Clinical trials: Retreatment
Diabetes Mellitus, Type 2
RF Vapor Ablation Retreatment of Duodenal Mucosa in Non-responders With Type-2 Diabetes Mellitus
The purpose of this study is to test the hypothesis that re-treatment of the duodenal mucosa with RF vapor ablation will result in improvement in glycemic parameters, without complications (bleeding/ stricture / perforation)…
- Trial name
- NCT06724822
- Testing
- RF Vapor Ablation
- Where
- Chile
- Volunteers
- 12 people
- Sponsor
- Aqua Medical, Inc.
Multiple Myeloma
Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab
The purpose of this study is to compare the efficacy (rate of very good partial response [VGPR] or better as best response as defined by the International Myeloma Working Group [IMWG] criteria) of daratumumab subcutaneous…
- Trial name
- NCT03871829
- Testing
- Carfilzomib 20 mg/m^2, Carfilzomib 70 mg/m^2, Dexamethasone 40 mg
- Where
- 108 sites in United States, Belgium and 11 more
- Volunteers
- 88 people
- Sponsor
- Janssen Research & Development, LLC
Osteoarthritis of Knee
A Clinical Trial to Evaluate the Safety and Efficacy of Retreatment With Intra-articular LBSA0103 Injections in the Patients With Osteoarthritis of the Knee
To assess the safety and efficacy of LBSA0103 (BDDE cross-linked sodium hyaluronate gel) when it is administered for the second time 26 weeks after its first administration in patients with osteoarthritis of the knee.
- Trial name
- NCT02122601
- Testing
- LBSA0103 (BDDE cross-linked sodium hyaluronate gel)
- Where
- South Korea
- Volunteers
- 174 people
- Sponsor
- LG Life Sciences
Intracranial Aneurysms
MAPS Trial: Matrix And Platinum Science
Primary Objectives: To establish Target Aneurysm Recurrence (TAR) rates for Matrix 2® and GDC® Coils used for the treatment of intracranial saccular aneurysms.
- Trial name
- MAPS (NCT00396981)
- Testing
- Matrix 2® coils for endovascular aneurysm occlusion, GDC® coils for endovascular aneurysm occlusion
- Where
- 43 sites in United States, Australia and 9 more
- Volunteers
- 626 people
- Sponsor
- Stryker Neurovascular
Chronic Spontaneous Urticaria
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the…
- Trial name
- NCT05513001
- Testing
- LOU064 (blinded), LOU064 (open label)
- Where
- 208 sites in United States, Argentina and 28 more
- Volunteers
- 696 people
- Sponsor
- Novartis Pharmaceuticals
Lupus Nephritis
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus Nephritis Previously Enrolled in Study U2970g
This is a Phase III, multicenter, extension study to evaluate the safety of rituximab administered on a scheduled basis approximately every 6 months.
- Trial name
- NCT00404157
- Testing
- Rituximab
- Sponsor
- Genentech, Inc.
Moderate to Severe Chronic Plaque-Type Psoriasis
4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
CAIN457A2304E1 was an extension study to two phase III studies, CAIN457A2304 and CAIN457A2307 (core studies). This extension study planned to collect up to four years of long-term safety, tolerability and efficacy data of…
- Trial name
- NCT01640951
- Testing
- AIN457 150 mg, AIN457 300 mg
- Where
- 111 sites in United States, Austria and 13 more
- Volunteers
- 675 people
- Sponsor
- Novartis Pharmaceuticals
Chin Augmentation
Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region
The primary objective of this study is to evaluate the safety of Restylane Lyft with Lidocaine for augmentation of the chin region 3 months after retreatment.
- Trial name
- NCT07566286
- Testing
- Restylane Lyft with Lidocaine
- Where
- 8 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Chronic Hepatitis C
Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV
This is an extension of ongoing study SCI-SCV-HCV-P2-001 in which subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with…
- Trial name
- NCT01310205
- Testing
- SCV-07
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- SciClone Pharmaceuticals
Lupus Erythematosus, Systemic
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
This is a Phase II/III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of rituximab compared with placebo when combined with a single stable background immunosuppressive…
- Trial name
- EXPLORER (NCT00137969)
- Testing
- Rituximab, Prednisone, Acetaminophen
- Where
- 65 sites in United States, Canada
- Volunteers
- 262 people
- Sponsor
- Genentech, Inc.
Rheumatoid Arthritis
A Study of Retreatment With Rituximab in Patients With Rheumatoid Arthritis Receiving Background Methotrexate
This is a Phase III, randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy of retreatment with rituximab in subjects with active rheumatoid arthritis (RA) who are receiving Methotrexate (MTX).
- Trial name
- SUNRISE (NCT00266227)
- Testing
- rituximab, methotrexate, folate
- Volunteers
- 559 people
- Sponsor
- Genentech, Inc.
CLL, Chronic Lymphocytic Leukemia
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
The purpose of this study is to investigate the efficacy and safety of tacabrutideg compared with investigator's choice (idelalisib plus rituximab [for CLL only] or bendamustine plus rituximab or venetoclax plus rituximab…
- Trial name
- CaDAnCe-302 (NCT06846671)
- Testing
- Tacabrutideg, Bendamustine, Idelalisib
- Where
- 132 sites in United States, Argentina and 12 more
- Volunteers
- 250 people
- Sponsor
- BeOne Medicines
Crohn's Disease
Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease
Protocol 610 is enrolling subjects who successfully achieved clinical benefit (reduction in Crohn's Disease Activity Index (CDAI) of at least 100 points) in Protocol 603.
- Trial name
- NCT00543374
- Testing
- PROCHYMAL adult human mesenchymal stem cells
- Where
- 58 sites in United States, Canada
- Volunteers
- 98 people
- Sponsor
- Mesoblast, Inc.
Lip Augmentation
A Multicenter, Open-Label Retreatment Study of the Safety and Effectiveness of PN40082 for Lip Augmentation
To evaluate the safety and efficacy of retreatment with PN40082 for lip augmentation.
- Trial name
- NCT04029519
- Testing
- PN40082
- Where
- 6 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Prollenium Medical Technologies Inc.
Psoriasis
Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis
The primary objective is to assess differences in PASI scores between Week 12 of Study C87040 [NCT00245765] and Week 12 of re-treatment in this study.
- Trial name
- NCT00329303
- Testing
- Certolizumab Pegol (Cimzia®)
- Where
- 14 sites in France, Germany
- Volunteers
- 71 people
- Sponsor
- UCB Pharma
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Retreatment With Intratumoral Diffusing Alpha Radiation Emitters
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT04540588
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 2 people
- Sponsor
- Alpha Tau Medical LTD.
Lymphoma, Non-Hodgkin
Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody
This multicenter study will determine the response rate, the complete response rate, duration of response, time to progression, time-to-treatment failure, safety, and survival following treatment with Iodine-131 Anti-B1 Antibody…
- Trial name
- NCT00938041
- Testing
- Tositumomab and Iodine I 131 Tositumomab
- Volunteers
- 32 people
- Sponsor
- GlaxoSmithKline
Hepatitis C, Chronic
An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure
This prospective, national, multicenter, observational study will evaluate in routine clinical practice the efficacy and safety of re-treatment with Pegasys (peginterferon alfa-2a) plus ribavirin or regimens containing…
- Trial name
- NCT01798576
- Testing
- Pegylated Interferon alfa-2a, Ribavirin
- Where
- Romania
- Volunteers
- 282 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Non-Hodgkin's
Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)
This is a Phase III, multicenter, global, open-label, single-arm, retreatment study of an investigational drug called galiximab in combination with an approved drug called rituximab in subjects with relapsed or refractory…
- Trial name
- NCT00384150
- Testing
- galiximab in combination with rituximab
- Volunteers
- 16 people
- Sponsor
- Biogen
Recurrent Respiratory Papillomatosis, Papillomavirus Infection
Zopa Retreatment and Vector Shedding in Adults With RRP
This open-label study evaluates safety, vector shedding, and retreatment efficacy of Zopapogene imadenovec (Zopa) in adults with recurrent respiratory papillomatosis (RRP).
- Conditions
- Recurrent Respiratory Papillomatosis, Papillomavirus Infection, Papillomaviridae
- Trial name
- NCT06538480
- Testing
- Zopapogene imadenovec (Zopa)
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Precigen, Inc